In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer

Cancer Gene Therapy

Volumn 17, Issue 6, 2010, Pages 420-428

  Tupper, J ^a   Stratford, M R ^a,b   Hill, S ^a,b   Tozer, G M ^a,c   Dachs, G U ^a,d  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

5Br IAA; HRP; IAA; Indoles; Mouse model; Xenograft

Indexed keywords

5 BROMOINDOLE 3 ACETIC ACID; HORSERADISH PEROXIDASE; INDOLEACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE THERAPY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; AREA UNDER CURVE; BROMINE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HORSERADISH PEROXIDASE; HUMANS; INDOLEACETIC ACIDS; MICE; MICE, SCID; NEOPLASMS; PRODRUGS; RADIOTHERAPY; TRANSGENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ARMORACIA RUSTICANA; MUS;

EID: 77952541595     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.86     Document Type: Article

References (35)

1. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16: 349-359.
2. Altaner C. Prodrug cancer gene therapy. Cancer Lett 2008; 270: 191-201.
3. Greco O, Folkes LK, Wardman P, Tozer GM, Dachs GU. Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther 2000; 7: 1414-1420.
4. Greco O, Rossiter S, Kanthou C, Folkes LK, Wardman P, Tozer GM et al. Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumour conditions. Mol Cancer Ther 2001; 1: 1-10.
5. Liao ZK, Zhou FX, Luo ZG, Zhang WJ, Xiong J, Bao J et al. Radio-activation of hTERT promoter in larynx squamous carcinoma cells: an 'indirected-activator' strategy in radio-gene-therapy. Oncol Rep 2008; 19: 281-286.
6. Sarrias MJ, Cabre P, Mart?nez E, Artigas F. Relationship between serotoninergic measures in blood and cerebrospinal fluid simultaneously obtained in humans. J Neurochem 1990; 54: 783-786.
7. Folkes LK, Wardman P. Oxidative activation of indole-3-acetic acids to cytotoxic species\a potential new role for plant auxins in cancer therapy. Biochem Pharmacol 2001; 61: 129-136.
8. Folkes LK, Dennis MF, Stratford MR, Candeias LP, Wardman P. Peroxidase-catalyzed effects of indole-3-acetic acid and analogues on lipid membranes, DNA, and mammalian cells in vitro. Biochem Pharmacol 1999; 57: 375-382.
9. Greco O, Dachs GU, Tozer GM, Kanthou C. Mechanisms of cytotoxicity induced by horseradish peroxidase/indole-3-acetic acid gene therapy. J Cell Biochem 2002a; 87: 221-232.
10. Greco O, Tozer GM, Dachs GU. Oxic and anoxic enhancement of radiation-mediated toxicity by horseradish peroxidase/indole-3-acetic acid gene therapy. Int J Radiat Biol 2002b; 78: 173-181.
11. Tupper J, Greco O, Tozer GM, Dachs GU. Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dimensional tumor model. Cancer Gene Ther 2004a; 11: 508-513.
12. Cemazar M, Sersa G, Wilson J, Tozer GM, Hart SL, Grosel A et al. Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther 2002; 9: 399-406.
13. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL. Tumor angiogenesis in node-negative breast carcinomas\relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 1994; 29: 109-116.
14. Folkes LK, Greco O, Dachs GU, Stratford MR, Wardman P. 5-Fluoroindole-3-acetic acid: a prodrug activated by a peroxidase with potential for use in targeted cancer therapy. Biochem Pharmacol 2002; 63: 265-272.
15. Parkins CS, Chadwick JA, Chaplin DJ. Enhancement of chlorambucil cytotoxicity by combination with flavone acetic acid in a murine tumour. Anticancer Res 1994; 14: 1603-1608.
16. Sheldon PW, Hill SA. Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice. Br J Cancer 1977; 35: 795-808.
17. Smith IE, Courtenay VD, Mills J, Peckham MJ. In vitro radiation response of cells from four human tumors propagated in immune-suppressed mice. Cancer Res 1978; 38: 390-392.
18. Tupper J, Tozer GM, Dachs GU. Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol. Br J Cancer 2004b; 90: 1858-1862.
19. Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 2000; 83: 811-816.
20. Hotter G, Closa D, Prats N, Pi F, Gelpi E, Rosello-Catafau J. Free radical enhancement promotes leucocyte recruitment through a PAF and LTB4 dependent mechanism. Free Radic Biol Med 1997; 22: 947-954.
21. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 1999; 6: 1305-1312.
22. Schuler W, Weiler IJ, Schuler A, Phillips R, Rosenberg N, Mak T et al. Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. Cell 1986; 46: 963-972.
23. Fuller RW, Lacefield WB, Kattau RW, Nickander RC, Snoddy HD. Myotonia produced by indoleacetic acid. Studies with related compounds and correlation with drug levels in tissues. Arch Int Pharmacodyn Ther 1971; 193: 48-60.
24. Yamada J, Sugimoto Y, Horisaka K. Indoleacetic acid-induced hypothermia and changes in serotonin metabolism in mice. J Pharmacobiodyn 1985; 8: 564-570.
25. Mirsky IA, Diengott D. Hypoglycemic action of indole-3-acetic acid by mouth in patients with diabetes mellitus. Proc Soc Exp Biol 1956; 93: 109-110.
26. Rysanek K, Vitek V. Increased excretion of 5-hydroxy-indole-acetic acid after the administration of 3-indole-acetic acid (heteroauxine). Experientia 1959; 15: 217-218.
27. Morse GD, Shelton MJ, O'Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 1993; 24: 101-123.
28. Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 1978; 24: 333-342.
29. Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacoki-netic study of its prodrug, CB1954. Clin Cancer Res 2001; 7: 2662-2668.
30. Atkinson G, Hall SJ. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology 1999; 54: 1098-1104.
31. Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ et al. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 2001; 3: 536-542.
32. Hanna NN, Mauceri HJ, Wayne JD, Hallahan DE, Kufe DW, Weichselbaum RR. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res 1997; 57: 4205-4209.
33. Kievit E, Nyati MK, Ng E, Stegman LD, Parsels J, Ross BD et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000; 60: 6649-6655.
34. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 2004; 64: 1396-1402.
35. Huang CH, Liao ZK, Zhou FX, Wang WF, Xie CH, Zhang HY et al. hTERT promoter enhances the radiosensitivity to gene-radiation therapy of human laryngeal carcinoma transplanted in nude mice. Zhonghua Zhong Liu Za Zhi 2008; 30: 733-736. Chinese.